Champions Oncology (NASDAQ:CSBR – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Profitability
This table compares Champions Oncology and Azenta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| Azenta | -20.63% | 1.18% | 0.97% |
Earnings & Valuation
This table compares Champions Oncology and Azenta”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $59.42 million | 1.12 | -$1.17 million | ($0.08) | -59.88 |
| Azenta | $593.82 million | 2.89 | -$55.76 million | ($2.76) | -14.19 |
Champions Oncology has higher earnings, but lower revenue than Azenta. Champions Oncology is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Champions Oncology and Azenta, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
Azenta has a consensus target price of $41.20, suggesting a potential upside of 5.21%. Given Azenta’s stronger consensus rating and higher probable upside, analysts plainly believe Azenta is more favorable than Champions Oncology.
Risk and Volatility
Champions Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Insider & Institutional Ownership
41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 10.9% of Azenta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Azenta beats Champions Oncology on 9 of the 13 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
